AIRNA, a biotechnology company specializing in RNA-editing therapeutics, has appointed Todd Bazemore as its new President and CEO. Bazemore, who has over 30 years of experience in the biopharmaceutical industry, is expected to lead the company through its next growth phase. His extensive background includes significant roles at Kala Bio, Santhera Pharmaceuticals, and Dyax Corp, where he focused on developing therapies for rare diseases. Under his leadership, AIRNA aims to advance its lead program, AIR-001, which targets alpha-1 antitrypsin deficiency and is currently in clinical trials. Rodger Novak, Executive Chair of AIRNA’s Board, praised Bazemore’s expertise in developing rare and orphan drugs, highlighting his ability to build value across innovative portfolios. Bazemore expressed enthusiasm for joining AIRNA at this pivotal time, emphasizing the potential of RNA editing to benefit millions globally. AIRNA's research is backed by pioneering work from its co-founders at leading universities, and the company is committed to expanding its pipeline of innovative therapies.